Emerging Technology Partners
South San Francisco, Californiaetpvc.com
Overview
Emerging Technology Partners (also known as ETP Capital) is a life sciences focused investment fund with a cross border investment focus. ETP supports portfolio companies by facilitating strategic alliances including cross-border partnerships, recruiting management, and acquiring new products and technologies to accelerate growth in both US and China. ETP invests as early as the seed stage and as late as post-IPO rounds.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Human Longevity | Aug 2024 | Series B | Co-investor |
| HerAnova Lifesciences | Dec 2023 | Seed | Co-investor |
| TCRCure Biopharma | Feb 2022 | Series B | Co-investor |
| Shanghai Bendao Gene Technology | Apr 2021 | Series A | Co-investor |
| Juventas Cell Therapy Ltd. | Nov 2020 | Series B | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
